[HTML][HTML] High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus
…, I Gunnarsson, J Dorschner, S Eketjäll, A Zickert… - Arthritis research & …, 2019 - Springer
Background and aim Interferons (IFNs) are considered to be key molecules in the pathogenesis
of systemic lupus erythematosus (SLE). We measured levels of type I, II and III IFNs in a …
of systemic lupus erythematosus (SLE). We measured levels of type I, II and III IFNs in a …
[HTML][HTML] IL-17 and IL-23 in lupus nephritis-association to histopathology and response to treatment
A Zickert, P Amoudruz, Y Sundström, J Rönnelid… - BMC immunology, 2015 - Springer
Background Recent studies indicate a central role for the IL-23/IL-17 axis in the pathogenesis
of lupus nephritis (LN) but the importance in the context of treatment outcome is unknown. …
of lupus nephritis (LN) but the importance in the context of treatment outcome is unknown. …
[HTML][HTML] Association of STAT4 Polymorphism with Severe Renal Insufficiency in Lupus Nephritis
K Bolin, JK Sandling, A Zickert, A Jönsen, C Sjöwall… - PloS one, 2013 - journals.plos.org
Lupus nephritis is a cause of significant morbidity in systemic lupus erythematosus (SLE) and
its genetic background has not been completely clarified. The aim of this investigation was …
its genetic background has not been completely clarified. The aim of this investigation was …
[HTML][HTML] B cell alterations during BAFF inhibition with belimumab in SLE
Background Systemic lupus erythematosus (SLE) is a systemic autoimmune disease, which
exhibits multiple B cell abnormalities including expanded populations of memory B cells and …
exhibits multiple B cell abnormalities including expanded populations of memory B cells and …
[HTML][HTML] Microparticles in the blood of patients with systemic lupus erythematosus (SLE): phenotypic characterization and clinical associations
…, A Vikerfors, JT Gustafsson, I Gunnarsson, A Zickert… - Scientific reports, 2016 - nature.com
Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by
circulating autoantibodies and the formation of immune complexes. In these responses, the …
circulating autoantibodies and the formation of immune complexes. In these responses, the …
TNF-α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus
…, S Pettersson, JT Gustafsson, A Zickert… - Lupus Science & …, 2018 - lupus.bmj.com
Objectives Composite criteria/indices are presently used to diagnose and monitor patients
with systemic lupus erythematosus (SLE). Biomarkers for these purposes would be helpful in …
with systemic lupus erythematosus (SLE). Biomarkers for these purposes would be helpful in …
Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus
…, C Sjöwall, A Jönsen, D Ramsköld, A Zickert… - Autoimmunity …, 2017 - Elsevier
Objectives Belimumab is the first biologic drug approved for Systemic Lupus Erythematosus
(SLE). Here, we aimed to investigate the effects of belimumab on clinical and serologic …
(SLE). Here, we aimed to investigate the effects of belimumab on clinical and serologic …
Cigarette smoking, antiphospholipid antibodies and vascular events in systemic lupus erythematosus
…, H Källberg, S Pettersson, A Zickert… - Annals of the …, 2015 - ard.bmj.com
Objective Smoking can induce autoantibodies in persons who are genetically predisposed
to rheumatoid arthritis. We investigated the association between smoking and …
to rheumatoid arthritis. We investigated the association between smoking and …
[HTML][HTML] Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis
A Zickert, K Palmblad, B Sundelin, S Chavan… - Arthritis research & …, 2012 - Springer
Introduction High mobility group box 1 protein (HMGB1) is a nuclear DNA binding protein
acting as a pro-inflammatory mediator following extracellular release. HMGB1 has been …
acting as a pro-inflammatory mediator following extracellular release. HMGB1 has been …
Four Systemic Lupus Erythematosus Subgroups, Defined by Autoantibodies Status, Differ Regarding HLA‐DRB1 Genotype Associations and Immunological and …
…, K Elvin, Y Ling Wu, S Eketjäll, A Zickert… - ACR open …, 2022 - Wiley Online Library
Objective The heterogeneity of systemic lupus erythematosus (SLE) constitutes clinical and
therapeutical challenges. We therefore studied whether unrecognized disease subgroups …
therapeutical challenges. We therefore studied whether unrecognized disease subgroups …